Ortopedia

TREATMENT OF SIMPLE BONE CYST WITH BONE MARROW CONCENTRATE AND EQUINE-DERIVED DEMINERALIZED BONE MATRIX INJECTION VERSUS METHYLPREDNISOLONE ACETATE INJECTIONS: A RETROSPECTIVE COMPARATIVE STUDY

2020
Autore : Peretti G., D'Amato R.

The use of an equine enzymatically deantigenated and demineralized bone paste in association with autologous BMC in patients with bone cysts

The aim of this study was to compare the outcome of intra-lesional autologous bone marrow concentrate (BMC) and equine derived demineralized bone matrix (EDDBM) injections with methylprednisolone acetate injections in patients with simple bone cyst. Clinical records and radiographs of 53 consecutive patients (37 females,and 16 males; mean age: 10.6+/-1.53 years) treated between 2006 and 2016 were retrospectively reviewed. At a minimum follow-up of 24 months, success rate (Neer/Cole score 3 and 4) was higher in EDDBM+BMC group (83.3% vs 58.6%; p=0.047).  Treatment with BMC+EDDBM injections may provide better results with a single procedure than 3 methylprednisolone acetate injections and represent an interesting alternative for the treatment of unicameral bone cysts. 

PRODUCTS USED: Osteoplant Activagen Injectable Paste

Acta Orthop Traumatol Turc
Logo Bioteck Academy


Vicenza
Sede Amministrativa e legale
via E. Fermi, 49
36057 Arcugnano, Vicenza (VI) - Italia
Tel. +39 0444 289366
Fax: +39 0444 285272


Contattaci


Torino
Centro Polifunzionale di produzione
Via G. Agnelli, 3
10020 Riva presso Chieri, Torino (TO) - Italia

Copyright © 2020 Bioteck S.p.A. - Privacy Policy - Cookie Policy